Harmony Biosciences (HRMY) Projected to Post Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is projected to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Harmony Biosciences to post earnings of $0.74 per share and revenue of $201.25 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $34.56 on Monday. The company’s fifty day moving average price is $36.57 and its 200 day moving average price is $35.81. Harmony Biosciences has a 12 month low of $28.14 and a 12 month high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The firm has a market capitalization of $1.97 billion, a P/E ratio of 16.38, a P/E/G ratio of 0.47 and a beta of 0.80.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 10,507 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sandip Kapadia sold 25,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Cantor Fitzgerald lifted their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Oppenheimer restated an “outperform” rating and issued a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Needham & Company LLC decreased their price target on Harmony Biosciences from $52.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Harmony Biosciences in a research report on Wednesday, February 19th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, Harmony Biosciences currently has an average rating of “Buy” and an average price target of $53.67.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.